DK3265482T3 - Integrin-targeterende protein og anvendelsesmåder deraf - Google Patents

Integrin-targeterende protein og anvendelsesmåder deraf

Info

Publication number
DK3265482T3
DK3265482T3 DK16762256.2T DK16762256T DK3265482T3 DK 3265482 T3 DK3265482 T3 DK 3265482T3 DK 16762256 T DK16762256 T DK 16762256T DK 3265482 T3 DK3265482 T3 DK 3265482T3
Authority
DK
Denmark
Prior art keywords
integrin
methods
targeting protein
targeting
protein
Prior art date
Application number
DK16762256.2T
Other languages
English (en)
Inventor
Zhi-Ren Liu
Chakra Ravi Turaga
jenny Yang
Original Assignee
Univ Georgia State Res Found
Proda Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia State Res Found, Proda Biotech Llc filed Critical Univ Georgia State Res Found
Application granted granted Critical
Publication of DK3265482T3 publication Critical patent/DK3265482T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/70557Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK16762256.2T 2015-03-06 2016-03-04 Integrin-targeterende protein og anvendelsesmåder deraf DK3265482T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129499P 2015-03-06 2015-03-06
PCT/US2016/021037 WO2016144815A1 (en) 2015-03-06 2016-03-04 Integrin-targeting protein and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3265482T3 true DK3265482T3 (da) 2026-01-12

Family

ID=56880437

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16762256.2T DK3265482T3 (da) 2015-03-06 2016-03-04 Integrin-targeterende protein og anvendelsesmåder deraf

Country Status (10)

Country Link
US (1) US20180044403A1 (da)
EP (2) EP4706760A2 (da)
JP (4) JP6789961B2 (da)
CN (1) CN107709354B (da)
AU (3) AU2016230009A1 (da)
CA (1) CA2978597A1 (da)
DK (1) DK3265482T3 (da)
ES (1) ES3058649T3 (da)
FI (1) FI3265482T3 (da)
WO (1) WO2016144815A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118028214B (zh) * 2022-12-30 2025-05-16 珠海市藤栢医药有限公司 过表达整合素的人脐静脉内皮细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA175122A (en) 1916-11-27 1917-02-13 Segmond Schwerin Ornamenting surface
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
EP1587912A2 (en) * 2003-01-30 2005-10-26 The General Hospital Corporation Methods of identifying and designing cell surface receptor inhibitors
JP2008518022A (ja) * 2004-10-27 2008-05-29 メディミューン,インコーポレーテッド 線維症関連疾患を治療するためのEphA2およびエフリンA1モジュレーター
US8227419B2 (en) * 2006-02-03 2012-07-24 Crc For Asthma And Airways Ltd. Method of treating conditions associated with airway tissue remodeling
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US9175063B2 (en) * 2010-07-13 2015-11-03 Georgia State University Research Foundation Anti-angiogenic agent and methods of using such agent
GB201013573D0 (en) * 2010-08-12 2010-09-29 Ucl Business Plc Treatment
WO2021009471A1 (en) 2019-07-18 2021-01-21 Total E&P Uk Limited A method of optimizing production from a hydrocarbon reservoir

Also Published As

Publication number Publication date
RU2017135220A (ru) 2019-04-05
EP3265482B1 (en) 2025-11-05
US20180044403A1 (en) 2018-02-15
JP2018510861A (ja) 2018-04-19
JP2023052154A (ja) 2023-04-11
JP2021046402A (ja) 2021-03-25
FI3265482T3 (fi) 2026-01-16
WO2016144815A1 (en) 2016-09-15
CN107709354B (zh) 2022-01-04
EP3265482A1 (en) 2018-01-10
EP4706760A2 (en) 2026-03-11
AU2020280987A1 (en) 2021-01-07
AU2024203940A1 (en) 2024-07-04
CN107709354A (zh) 2018-02-16
JP6789961B2 (ja) 2020-11-25
JP2025078632A (ja) 2025-05-20
EP3265482A4 (en) 2018-11-21
RU2017135220A3 (da) 2019-07-24
CA2978597A1 (en) 2016-09-15
AU2016230009A1 (en) 2017-10-12
ES3058649T3 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
IL271025A (en) Multibiotic agents and methods of using the same
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL282372A (en) Haploid induction compositions and methods for use therefor
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
IL255269A (en) Compositions of obeticholic acid and methods of use
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3514151T3 (da) Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
PL3565828T3 (pl) Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
HUE054093T2 (hu) Anti-HtrA1 antitestek és azok alkalmazási eljárásai